期刊文献+

神经生长因子联合溴隐亭对垂体GH3细胞的抑制作用 被引量:3

Inhibition effects of nerve growth factor and bromocriptine on proliferation of pituitary adenoma GH3 cells
下载PDF
导出
摘要 目的探讨神经生长因子(NGF)联合溴隐亭对垂体腺瘤GH3细胞增殖的影响。方法在无血清的培养条件下,将GH3细胞分成3组:对照组、溴隐亭组、NGF+溴隐亭组,采用CCK-8法检测不同药物干预后GH3细胞的成活率。结果与对照组比较,NGF干预后GH3细胞的形态无明显改变。单独溴隐亭治疗对GH3细胞增殖的抑制作用不明显,而NGF干预后2、4、6d分别再给予溴隐亭治疗则对GH3细胞增殖均有明显抑制作用(P〈0.01),其中NGF干预后4d及6d时溴隐亭的抑制效果更明显。结论NGF能促进溴隐亭对GH3细胞增殖的抑制作用。 Objective To investigate the effects of nerve growth factor (NGF) and bromocriptine(BC)on the proliferation of pituitary adenoma GH3 cells in vitro. Methods In serum-free culture conditions, GH3 cells were divided into 3 groups: control, bromocriptine and NGF + bromocriptine. The effects on proliferation of GH3 cells were tested by CCK-8 assay. Results Compared with the control group, bromocriptine alone had no inhibition effects on proliferation of GH3 cells (P〉 0.05 ). However, proliferation of GH3 cells was effectively inhibited by bromocriptine on d2, d4, d6 after NGF treatment(P〈 0.01 ). Conclusion NGF can enhance the inhibition effects of bromocriptine on proliferation of pituitary adenoma GH3 cell in vitro.
出处 《浙江医学》 CAS 2011年第8期1115-1116,1119,共3页 Zhejiang Medical Journal
基金 国家自然科学基金项目(30800347) 温州市科技计划项目(Y20080226)
关键词 垂体腺瘤 神经生长因子 溴隐亭 GH3细胞 Pituitary adenoma Nerve growth factor Bromocriptine GH3 cells
  • 相关文献

参考文献12

  • 1Casanueva F F,Molitch M E,Schlechte J A,et al.Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas[J].Clin Endocrinol(Oxf),2006,65:265-273.
  • 2Molitch M E.Pharmacologic resistance in prolactinoma patients[J].Pituitary,2005,8;43-52.
  • 3Pivonello R,Matrone C,Filippella M,et al.Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors:comparison with the effectiveness of cabergoline treatment[J].J Clin Endocrinol Metab,2004,89:1674-1683.
  • 4苏志鹏,吴哲褒,于春江.泌乳素腺瘤耐溴隐亭治疗的研究进展[J].中华神经外科杂志,2006,22(6):386-387. 被引量:8
  • 5Fiorentini C,Guerra N,Facchetti M,et al.Nerve growth factor regulates dopamine D2 receptor expression in prolactinoma cell lines via P75NGFR-mediated activation of nuclear factor-κB[J].Mol Endocrinol,2002,16:353-366.
  • 6Greenman Y,Tordjman K,Osher E,et al.Postoperative treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists decreases tumour remnant growth[J].Clin Endocrinol(Oxf),2005,63:39-44.
  • 7Colao A,Di Somma C,Pivonello R,et al.Medical therapy for clinically non-functioning pituitary adenomas[J].Endocr-Relat Cancer,2008,15:905-915.
  • 8Caccavelli L,Feron F,Morange I,et al.Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas[J].Neuroendocrinology,1994,60:314-322.
  • 9Passos V Q,Fortes M A H Z,Neto D G,et al.Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists[J].Neuroendocrinology,2009,89:163-170.
  • 10Wu Z B,Zheng W M,Su Z P,et al.Expression of D2R mRNA isoforms and ER mRNA isoforms in prolactinomas:correlation with the response to bromocriptine and with tumor biological behavior[J].J Neuro-Oncol,2010,99:25-32.

二级参考文献26

  • 1马驰原,卢亦成,史继新,任常春,朱景德,顾健人.垂体腺瘤双重靶向性基因治疗的实验研究[J].中华医学杂志,2005,85(4):262-266. 被引量:5
  • 2吴哲褒,于春江.溴隐亭治疗侵袭性巨大泌乳素腺瘤的长期随访结果[J].中华神经外科杂志,2005,21(3):131-137. 被引量:31
  • 3袁玉会,董欣明,于宏伟,关俊宏,王成林.伽玛刀治疗分泌型垂体腺瘤120例分析[J].中华外科杂志,2006,44(6):416-419. 被引量:9
  • 4Molitch ME. Dopamine resistance of prolactinomas. Pituitary, 2003,6 : 19-27.
  • 5Pellegrini I, Costa R, Grisoli F, et al. Abnormal dopamine sensitivity in some human prolactinomas. Horm Res, 1989, 31 : 19-23.
  • 6Morange I, Barlier A, Pellegrini I, et al. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagoline and outcome of pregnancy. Eur J Endocrinol, 1997, 135: 413-420.
  • 7Sarno AD, Landi ML, Cappabianca P, et al. Resistance to cabergoline as compared with bromoefiptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab, 2001,86: 5256-5261.
  • 8Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res,1998, 49 : 250-253.
  • 9Popadic A, Witzmann A, Buchfelder M, et al. Malignant prolactinoma case report and review of the literature. Surg Neurol,1999, 51 : 47-55.
  • 10Caccavelli L, Feron F, Morange I, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine resistant prolactinomas. Neuroendocrinol, 1994, 60: 314-322.

共引文献10

同被引文献24

引证文献3

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部